Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
BMY Stock News and Mentions of Bristol-Myers Squibb Company Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Bristol-Myers Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Bristol-Myers Squibb Company (BMY).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Bristol-Myers stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Bristol-Myers Squibb Company (BMY)
April 28, 2024 (12:30) / "Motley Fool" (by George Budwell)
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
This small-cap biotech stock is surging. Time to buy?
In Article Trend: Neutral
April 26, 2024 (15:34) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Rebound Amid Big-Cap Earnings: Weekly Review
Stock Market Rebounds. Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
April 26, 2024 (12:25) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
In Article Trend: Neutral
April 26, 2024 (06:59) / "Benzinga" (by Avi Kapoor)
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points - Chevron ( NYSE:CVX ) , Bristol-Myers Squibb ( NYSE:BMY )
The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the "Fear" zone on Thursday. U.S. stocks settled lower on Thursday, following the release of economic reports.
In Article Trend: Neutral
April 26, 2024 (02:16) / "Benzinga" (by Zacks)
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat - ADMA Biologics ( NASDAQ:ADMA ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Bristol-Myers Squibb Company BMY reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05.
In Article Trend: Neutral
April 25, 2024 (23:30) / "Motley Fool" (by Motley Fool Transcribing)
Alphabet ( GOOGL ) Q1 2025 Earnings Call Transcript
GOOGL earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (20:45) / "PR Newswire" (by Inc.)
Mahesh Krishnan Elected to Halozyme's Board of Directors
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( "Halozyme" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
In Article Trend: Somewhat-Bullish
April 25, 2024 (18:32) / "Benzinga" (by Avi Kapoor)
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results - ATN International ( NASDAQ:ATNI ) , Bristol-Myers Squibb ( NYSE:BMY )
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling by around 100 points on Thursday. The Dow traded down 1.20% to 37,998.27 while the NASDAQ fell 0.85% to 15,578.58. The S&P 500 also fell, dropping, 0.70% to 5,035.88. Materials shares rose by 0.7% on Thursday.
In Article Trend: Neutral
April 25, 2024 (18:28) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
In Article Trend: Neutral
April 25, 2024 (16:23) / "Benzinga" (by Vandana Singh)
Why Is Bristol Myers Squibb Stock Trading Lower On Thursday? - Bristol-Myers Squibb ( NYSE:BMY )
Thursday, Bristol Myers Squibb & Co BMY posted first-quarter revenues of $11.9 billion, beating the consensus of $11.5 billion, an increase of 5% year-over-year, or 6% when adjusted for foreign exchange impacts, primarily driven by Eliquis, Reblozyl, and Opdualag, partially offset by Opdivo and ...
In Article Trend: Neutral
April 25, 2024 (15:58) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates ( Revised )
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
In Article Trend: Neutral
April 25, 2024 (15:57) / "Motley Fool" (by Keith Speights)
Why Bristol Myers Squibb Stock Is Sinking Today
Investors didn't like the biopharmaceutical company's updated guidance.
In Article Trend: Somewhat-Bullish
April 25, 2024 (15:48) / "Zacks Commentary" (by Zacks Equity Research)
Bristol-Myers ( BMY ) Q1 Loss Narrower Than Expected, Sales Beat
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
In Article Trend: Neutral
April 25, 2024 (15:30) / "Motley Fool" (by Motley Fool Transcribing)
Bristol Myers Squibb ( BMY ) Q1 2024 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (14:45) / "Motley Fool" (by David Jagielski)
Is Bristol Myers Squibb Stock a Millionaire Maker?
Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.
In Article Trend: Somewhat-Bullish
April 25, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
In Article Trend: Neutral
April 25, 2024 (12:30) / "Investors Business Daily" (by ALLISON GATLIN)
How Big Pharma Is Taking A Page Out Of Novartis' Playbook
Biotech Stocks: Big Pharma Eyes $25 Billion Radiopharmaceuticals Market Investor's Business Daily ...
In Article Trend: Neutral
April 25, 2024 (11:35) / "CNBC" (by Annika Kim Constantino)
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
In Article Trend: Neutral
April 25, 2024 (11:31) / "Investors Business Daily" (by Investor's Business Daily)
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca, Sanofi Jump On First-Quarter Earnings. Bristol Myers Lags Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (10:17) / "Benzinga" (by Shanthi Rexaline)
Meta, IBM Drag Nasdaq Futures Lower: What's Driving Premarket Action - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.'s META lukewarm second-quarter revenue guidance and commentary regarding investment punctured the stock, while International Business Machines Corp.
In Article Trend: Neutral
April 24, 2024 (16:05) / "Zacks Commentary" (by Sweta Killa)
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
In Article Trend: Neutral
April 24, 2024 (13:19) / "Zacks Commentary" (by Ahan Chakraborty)
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
In Article Trend: Somewhat-Bullish
April 23, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
NeoGenomics ( NEO ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 23, 2024 (12:25) / "Benzinga" (by Vandana Singh)
Why Is Novartis Stock Trading Higher On Tuesday? - Novartis ( NYSE:NVS )
Shares of Swiss pharma giant Novartis AG NVS after the company raised its full-year guidance following better-than-expected first-quarter results. Novartis reported first-quarter adjusted EPS of $1.80, up 17% year over year ( 23% on constant currency ) , beating the consensus of $1.67.
In Article Trend: Somewhat-Bullish
April 23, 2024 (05:00) / "GlobeNewswire" (by Novartis Pharma AG)
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LR ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (17:56) / "Zacks Commentary" (by Zacks Equity Research)
Bristol-Myers' ( BMY ) to Report Q1 Earnings: What You Should Know
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
In Article Trend: Somewhat-Bullish
April 22, 2024 (15:09) / "Benzinga" (by Globe Newswire)
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
CAMBRIDGE, Mass., April 22, 2024 ( GLOBE NEWSWIRE ) -- Anthos Therapeutics, Inc. ( Anthos ) , is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences ( BXLS ) , today announced the appointment of Bill Meury as CEO and member of ...
In Article Trend: Neutral
April 22, 2024 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Curious about Bristol Myers ( BMY ) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
In Article Trend: Neutral
April 22, 2024 (08:29) / "Barrons" (by Joe Woelfel)
Nvidia, Tesla, Super Micro, Verizon, Informatica, Coinbase, Cardinal Health, and More Stock Market Movers
Nvidia, Tesla, Super Micro, Salesforce, Verizon, and More Stock Market Movers ...
In Article Trend: Neutral
April 21, 2024 (21:45) / "Benzinga" (by Shanthi Rexaline)
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
As the market runs into rough weather, the importance of the upcoming week's earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. TSLA, Meta Platforms, Inc. META, Microsoft Corp. MSFT and Alphabet, Inc. GOOGL ( GOOG ) .
In Article Trend: Neutral
April 21, 2024 (10:18) / "Forbes" (by Bill Stone)
Better Earnings Don't Stop The Plunge In Stocks
The earnings season remained slow out of the gate, with only 41 S&P 500 companies reporting. Banks continued to be a large contingent of the reporters, which boosted the sector's earnings expectations for the quarter as most banks had better-than-expected earnings.
In Article Trend: Somewhat-Bullish
April 20, 2024 (09:23) / "Motley Fool" (by David Jagielski)
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
These stocks pay between 3.2% and 6.7% in dividends.
In Article Trend: Somewhat-Bullish
April 19, 2024 (19:16) / "Benzinga" (by Benzinga Insights)
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics - Bristol-Myers Squibb ( NYSE:BMY )
Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 8 unusual trades. Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:28) / "Benzinga" (by Vandana Singh)
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies - Johnson & Johnson ( NYSE:JNJ ) , Novartis ( NYSE:NVS ) , Gilead Sciences ( NASDAQ:GILD ) , Bristol-Myers Squibb ( NYSE:BMY )
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings-the highest safety-related caution for medications-for all chimeric antigen receptor ( CAR ) T-cell therapies.
In Article Trend: Neutral
April 19, 2024 (12:15) / "Motley Fool" (by David Jagielski)
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Earnings Preview: Bristol Myers Squibb ( BMY ) Q1 Earnings Expected to Decline
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 18, 2024 (11:00) / "PR Newswire" (by Pathios Therapeutics)
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy ... PR ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (15:02) / "Zacks Commentary" (by Zacks Equity Research)
2seventy bio ( TSVT ) Rises More Than 50% in 3 Months: Here's Why
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
In Article Trend: Somewhat-Bullish
April 17, 2024 (13:30) / "Forbes" (by William A. Haseltine)
Checkpoint Inhibitors: A New Hope for Cancer Treatment
This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy. Here, we explore the history behind this revolutionary discovery. Future installments will delve deeper into the treatment's mechanism and the latest research expanding the field.
In Article Trend: Neutral
April 17, 2024 (13:30) / "Motley Fool" (by Prosper Junior Bakiny)
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels.
In Article Trend: Somewhat-Bullish
April 16, 2024 (20:10) / "GlobeNewswire" (by Ultimovacs ASA)
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
• Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1's potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC ...
In Article Trend: Neutral
April 16, 2024 (07:42) / "Stocknews.com" (by Defense World Staff)
Bristol-Myers Squibb ( NYSE:BMY ) Cut to "Buy" at StockNews.com
StockNews.com cut shares of Bristol-Myers Squibb ( NYSE:BMY - Free Report ) from a strong-buy rating to a buy rating in a research note published on Monday morning.
In Article Trend: Somewhat-Bullish
April 16, 2024 (03:01) / "CNBC" (by Ernestine Siu)
These are the top 5 companies to work for in India, according to LinkedIn
LinkedIn has released its eighth annual list of top companies to work for in India. Companies that prioritized its employees' experience and growth dominated.
In Article Trend: Somewhat-Bullish
April 15, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
In Article Trend: Neutral
April 15, 2024 (17:31) / "Benzinga" (by Benzinga Insights)
Market Whales and Their Recent Bets on BMY Options - Bristol-Myers Squibb ( NYSE:BMY )
Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (14:06) / "Investors Business Daily" (by ALLISON GATLIN)
Biotech Stock Hits 2024 Low Side Effects In Rabbits Torpedo Schizophrenia Drug
Neumora Therapeutics ( NMRA ) said Monday the Food and Drug Administration put its schizophrenia drug on hold after rabbits who received it experienced convulsions. In response, the biotech stock plunged.
In Article Trend: Neutral
April 15, 2024 (13:30) / "Motley Fool" (by George Budwell)
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:00) / "Motley Fool" (by George Budwell)
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
In Article Trend: Somewhat-Bullish
April 14, 2024 (11:00) / "Forbes" (by Bill Stone)
Inflation And Banks Drag Stocks Lower Despite Earnings
The earnings season began slowly last week, with only 10 S&P 500 companies reporting. Banks were a large contingent of the reporters, which boosted the sector's earnings expectations for the quarter as all the banks reported better-than-expected earnings.
In Article Trend: Neutral
April 14, 2024 (01:58) / "Forbes" (by Teresa Ghilarducci)
CWA Union Fights Back Against So-Called Pension De-Risking
Before its bankruptcy in 1991, Executive Life Insurance Company accepted transfer contracts from companies to pay their retirees' pensions instead of the companies defined benefit pension plan.
In Article Trend: Neutral
April 12, 2024 (18:45) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb ... PR ...
In Article Trend: Neutral
April 12, 2024 (18:18) / "Benzinga" (by Vandana Singh)
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom - Agenus ( NASDAQ:AGEN )
Friday, Agenus Inc AGEN released updated results from its Phase 1 clinical trial of botensilimab and balstilimab ( BOT/BAL ) combination therapy for metastatic colorectal cancer ( CRC ) that is not microsatellite instability-high ( MSS ) or deficient mismatch repair ( dMMR ) .
In Article Trend: Neutral
April 12, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Peering Into Bristol-Myers Squibb's Recent Short Interest - Bristol-Myers Squibb ( NYSE:BMY )
Bristol-Myers Squibb's BMY short percent of float has risen 13.58% since its last report. The company recently reported that it has 37.25 million shares sold short, which is 1.84% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:22) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
April 11, 2024 (20:46) / "Benzinga" (by Benzinga Insights)
This Is What Whales Are Betting On Bristol-Myers Squibb - Bristol-Myers Squibb ( NYSE:BMY )
Investors with a lot of money to spend have taken a bearish stance on Bristol-Myers Squibb BMY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.
In Article Trend: Somewhat-Bullish
April 10, 2024 (17:19) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
In Article Trend: Somewhat-Bullish
April 10, 2024 (14:47) / "Benzinga" (by Upwallstreet)
The Pharmaceutical Industry Finds Itself At A Historical Crossroads - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb BMY, Merck & Co Inc MRK, Pfizer Inc PFE and Johnson & JohnsonJNJ are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk.
In Article Trend: Neutral
April 10, 2024 (11:00) / "PR Newswire" (by TORL Biotherapeutics LLC)
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate ( ADC ) Oncology Pipeline
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical ... PR ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (10:04) / "Motley Fool" (by Cory Renauer)
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
These reliable dividend payers offer yields of 3.3% and better at recent prices.
In Article Trend: Bullish
April 9, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.60, marking a +0.98% move from the previous day.
In Article Trend: Neutral
April 9, 2024 (21:41) / "PR Newswire" (by DelveInsight Business Research)
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:37) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai's approach to AI.
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:00) / "GlobeNewswire" (by Ultimovacs ASA)
Ultimovacs - Invitation to Business Update on April 17, 2024
Oslo, April 9, 2024: Ultimovacs ASA ( "Ultimovacs" ) ( OSE ULTI ) , Ultimovacs ASA ( "Ultimovacs" ) ( OSE ULTI ) , a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company will host a webcast on April 17, 2024, at 11:00.
In Article Trend: Neutral
April 9, 2024 (17:27) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Reports Positive Colorectal Cancer Study Data
Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
In Article Trend: Somewhat-Bullish
April 9, 2024 (08:21) / "Motley Fool" (by Cory Renauer)
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
In Article Trend: Somewhat-Bullish
April 8, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.
In Article Trend: Somewhat-Bullish
April 8, 2024 (20:45) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY - Bristol-Myers Squibb ( NYSE:BMY )
NEW YORK, April 08, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ( "Bristol Myers" or the "Company" ) BMY. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
April 8, 2024 (18:00) / "Benzinga" (by Vandana Singh)
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation - Bristol-Myers Squibb ( NYSE:BMY )
Monday, Bristol Myers Squibb & Co BMY released data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating Krazati ( adagrasib ) in combination with cetuximab for previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
In Article Trend: Somewhat-Bullish
April 8, 2024 (17:27) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets FDA Nod for Label Expansion of Abecma
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:31) / "Benzinga" (by Vandana Singh)
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics - Bristol-Myers Squibb ( NYSE:BMY )
Saturday, Bristol Myers Squibb & Co BMY released interim long-term safety, tolerability, and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT ( xanomeline-trospium ) in adults with schizophrenia.
In Article Trend: Neutral
April 8, 2024 (07:34) / "Motley Fool" (by Cory Renauer)
Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
In Article Trend: Neutral
April 5, 2024 (17:37) / "Benzinga" (by Vandana Singh)
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer - 2seventy bio ( NASDAQ:TSVT ) , Bristol-Myers Squibb ( NYSE:BMY )
Friday, the FDA approved Bristol-Myers Squibb Company BMY and 2seventy Bio Inc's TSVT Abecma ( idecabtagene vicleucel; ide-cel ) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale - Akoya Biosciences ( NASDAQ:AKYA )
MARLBOROUGH, Mass., April 05, 2024 ( GLOBE NEWSWIRE ) -- Akoya Biosciences, Inc., AKYA, The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American ...
In Article Trend: Neutral
April 4, 2024 (23:20) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb ... PR ...
In Article Trend: Neutral
April 4, 2024 (20:43) / "Benzinga" (by Zacks)
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More - Disc Medicine ( NASDAQ:IRON ) , Bristol-Myers Squibb ( NYSE:BMY )
Pipeline and regulatory updates continue to be in focus in the biotech sector. While nothing much came out of bigwigs apart from a few, shares of clinical-stage biotechs like Disc Medicine, Inc. IRON and Verve Therapeutics VERV plunged on disappointing updates.
In Article Trend: Neutral
April 4, 2024 (17:21) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
In Article Trend: Neutral
April 4, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search Bristol Myers Squibb Company ( BMY ) : Here is What You Need to Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
April 4, 2024 (13:00) / "Forbes" (by Juergen Eckhardt)
An Ingenious Technology Could Change Both Medicine And Agriculture
Two decades ago, the American biochemists Craig Crews and Ray Deshaies hit on a revolutionary new approach for targeting disease-causing proteins. As Crews puts it, the underlying idea was "to do drug development differently."
In Article Trend: Neutral
April 4, 2024 (12:45) / "Benzinga" (by Globe Newswire)
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
STUDIO CITY, Calif., April 04, 2024 ( GLOBE NEWSWIRE ) -- At the conclusion of this year's Myeloma Action Month, the International Myeloma Foundation ( IMF ) was truly grateful and overwhelmed by everyone's support in making the annual campaign a global success -with over 52 million reached in ...
In Article Trend: Bullish
April 3, 2024 (13:14) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Wins EC Nod for Reblozyl Label Expansion
Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
In Article Trend: Neutral
April 3, 2024 (12:00) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific ( TCB ) Collaboration with Astellas
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date ...
In Article Trend: Neutral
April 3, 2024 (08:19) / "Motley Fool" (by Cory Renauer)
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
These stocks could rocket higher, but they also present significant risks.
In Article Trend: Neutral
April 2, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Stock Moves -0.47%: What You Should Know
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.74, signifying a -0.47% move from its prior day's close.
In Article Trend: Neutral
April 2, 2024 (12:30) / "PR Newswire" (by Alexandria Real Estate Equities)
Alexandria Real Estate Equities, Inc. Named One of the Most Trustworthy Companies in America by Newsweek for Second Consecutive Year
Alexandria Real Estate Equities, Inc. Named One of the Most Trustworthy Companies in America by Newsweek for ... PR ...
In Article Trend: Bullish
April 2, 2024 (12:05) / "GlobeNewswire" (by Inc)
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines ( BCMs )
Be Biopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs Be Biopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:05) / "Benzinga" (by Globe Newswire)
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines ( BCMs ) - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., April 02, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:46) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers' ( BMY ) Zeposia Fails Crohn's Disease Study
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
In Article Trend: Neutral
April 1, 2024 (13:44) / "Benzinga" (by Vandana Singh)
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details - Bristol-Myers Squibb ( NYSE:BMY )
Thursday, Bristol Myers Squibb & Co BMY announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE trial program of Zeposia ( ozanimod ) in adult patients with moderate to severe active Crohn's disease.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:25) / "GlobeNewswire" (by Inc.)
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
BETHESDA, Md., April 01, 2024 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc. ( Nasdaq: GANX ) ( "Gain", or the "Company" ) , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies, today announces the appointment of ...
In Article Trend: Neutral
April 1, 2024 (13:00) / "PR Newswire" (by Overhaul)
Overhaul's Q1 Triumphs: Leading the Way in Supply Chain Excellence
AUSTIN, Texas, April 1, 2024 /PRNewswire/ -- Overhaul, a software-based supply-chain visibility, risk, compliance, and insurance solution for the world's leading brands, has announced a notable series of recognitions in the first quarter of 2024.
In Article Trend: Bullish
April 1, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Autolus Therapeutics Announces Changes to its Board of Directors - Autolus Therapeutics ( NASDAQ:AUTL )
LONDON, April 01, 2024 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director.
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:00) / "GlobeNewswire" (by Autolus Inc.)
Autolus Therapeutics Announces Changes to its Board of Directors
LONDON, April 01, 2024 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc ( Nasdaq: AUTL ) , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive ...
In Article Trend: Neutral
March 31, 2024 (15:07) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY - Bristol-Myers Squibb ( NYSE:BMY )
NEW YORK, March 31, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ( "Bristol Myers" or the "Company" ) BMY. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 29, 2024 (12:21) / "GlobeNewswire" (by Molecular Templates)
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, March 29, 2024 ( GLOBE NEWSWIRE ) -- Molecular Templates, Inc. ( Nasdaq: MTEM, "Molecular Templates," or "MTEM" ) , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ( "ETBs" ) ...
In Article Trend: Neutral
March 28, 2024 (12:15) / "Motley Fool" (by Prosper Junior Bakiny)
Is Bristol Myers Squibb Stock a Buy?
The company is going through a rough patch.
In Article Trend: Neutral
March 28, 2024 (12:00) / "Investors Business Daily" (by ALLISON GATLIN)
Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?
Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...
In Article Trend: Neutral
March 28, 2024 (11:30) / "GlobeNewswire" (by Perspective Therapeutics)
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
SEATTLE, March 28, 2024 ( GLOBE NEWSWIRE ) -- Perspective, Therapeutics, Inc. ( NYSE AMERICAN: CATX ) , a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial ...
In Article Trend: Neutral
March 27, 2024 (23:53) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb ... PR ...
In Article Trend: Neutral
March 27, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Rises Higher Than Market: Key Facts
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 27, 2024 (21:18) / "Forbes" (by Sara Dorn)
Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy
Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the "outrageously high price has the potential to bankrupt Medicare, the American people and our entire ...
In Article Trend: Neutral
March 27, 2024 (13:20) / "Benzinga" (by Vandana Singh)
Why Is Merck Stock Trading Higher On Wednesday? - Merck & Co ( NYSE:MRK )
Tuesday, the FDA approved Merck & Co Inc's MRK Winrevair ( sotatercept-csrk ) , for injection, 45mg, 60mg for adults with pulmonary arterial hypertension ( PAH ) to increase exercise capacity, improve WHO functional class ( FC ) , and reduce the risk of clinical worsening events.
In Article Trend: Somewhat-Bullish
March 25, 2024 (20:15) / "PR Newswire" (by Q32 Bio)
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
-- Q32 Bio to focus on advancement of bempikibart ( ADX-914 ) in ongoing atopic dermatitis ( AD ) and alopecia areata ( AA ) Phase 2 clinical trials and commencement of ADX-097 Phase 2 renal basket clinical trial in patients with complement disorders --
In Article Trend: Somewhat-Bullish
March 25, 2024 (14:05) / "Zacks Commentary" (by Zacks Equity Research)
Bayer ( BAYRY ) Banks on Pipeline Progress Amid Challenges
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
In Article Trend: Neutral
March 25, 2024 (11:00) / "Forbes" (by Dmitry Reykhart)
Council Post: What's Driving Big Pharma's Recent Market Performance?
What's Driving Big Pharma's Recent Market Performance? Forbes ...
In Article Trend: Neutral
March 23, 2024 (20:45) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY - Bristol-Myers Squibb ( NYSE:BMY )
NEW YORK, March 23, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ( "Bristol Myers" or the "Company" ) BMY. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (14:30) / "Motley Fool" (by Adam Spatacco)
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.
In Article Trend: Somewhat-Bullish
March 22, 2024 (09:38) / "Money Control"
M&A is back. Expect losers to outnumber winners
Many publicly traded companies are now sitting on sizeable cash reserves and borrowing costs appear to be stable. Buyout funds, too, are awash with cash and itching to deploy it. The worry must be that financial firepower, frustration and a fear of missing out make for ill-disciplined ...
In Article Trend: Neutral
March 21, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.
In Article Trend: Somewhat-Bullish
March 21, 2024 (13:10) / "Benzinga" (by Vandana Singh)
Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer - Bristol-Myers Squibb ( NYSE:BMY )
Wednesday, the European Commission approved Bristol Myers Squibb & Co's BMY Abecma ( idecabtagene vicleucel; ide-cel ) for relapsed and refractory multiple myeloma who have received at least two prior therapies and have demonstrated disease progression on the last therapy.
In Article Trend: Somewhat-Bullish
March 21, 2024 (11:53) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets EC Nod for Abecma's Label Expansion
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (15:49) / "Zacks Commentary" (by Zacks Equity Research)
AstraZeneca ( AZN ) to Buy Fusion Pharmaceuticals for $2.4B
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
In Article Trend: Neutral
March 20, 2024 (15:30) / "Benzinga" (by The Bamboo Works)
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy - Johnson & Johnson ( NYSE:JNJ ) , Bristol-Myers Squibb ( NYSE:BMY )
GenScript's cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend's Carvykti is expected to hit annual production capacity of 10,000 doses by the end of 2025
In Article Trend: Neutral
March 20, 2024 (14:00) / "Forbes" (by Alex Knapp)
This Startup Is One Step Closer To Making Drugs In Space
n June 12, 2023, a SpaceX Falcon 9 rocket successfully lifted multiple satellites to orbit, among them the W-1 belonging to California-based Varda Space Industries.
In Article Trend: Somewhat-Bullish
March 20, 2024 (10:00) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Mainz, Germany, March 20, 2024 ( GLOBE NEWSWIRE ) - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
In Article Trend: Somewhat-Bullish
March 19, 2024 (21:35) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb ... PR ...
In Article Trend: Neutral
March 19, 2024 (17:15) / "Benzinga" (by Benzinga Insights)
Check Out What Whales Are Doing With BMY - Bristol-Myers Squibb ( NYSE:BMY )
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb BMY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
March 19, 2024 (15:48) / "Barrons" (by Jacob Sonenshine)
The Stock Market Is Expensive. The Best Way to Buy Cheap Stocks.
Most stocks have recently become more expensive. Buying cheap stocks is a decent strategy, but there's a right way to do it. The Invesco S&P 500 Equal Weight exchange-traded fund, which weights each stock in the index equally and therefore shows the movement of the average stock, is up 23% since ...
In Article Trend: Neutral
March 19, 2024 (11:26) / "Benzinga" (by Vandana Singh)
Why Is Fusion Pharmaceuticals Stock Trading Higher Today? - AstraZeneca ( NASDAQ:AZN ) , Fusion Pharmaceuticals ( NASDAQ:FUSN )
Tuesday, AstraZeneca Plc AZN agreed to acquire Fusion Pharmaceuticals Inc FUSN for $21.00 per share in cash plus a non-transferable contingent value right ( CVR ) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:00) / "Benzinga" (by PR.com)
Bench International Adds Industry Veteran Dr. Renee P. Tannenbaum to Executive Leadership Team
San Diego, CA March 19, 2024 -- ( PR.com ) -- Bench International, a leading global executive search firm, proudly announces the appointment of Renee P. Tannenbaum, PharmD, as Head of Corporate Development.
In Article Trend: Bullish
March 18, 2024 (20:40) / "Benzinga" (by Globe Newswire)
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Arvinas ( NASDAQ:ARVN )
NEW HAVEN, Conn., March 18, 2024 ( GLOBE NEWSWIRE ) -- Arvinas, Inc.
In Article Trend: Somewhat-Bullish
March 18, 2024 (20:40) / "GlobeNewswire" (by Arvinas Inc.)
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635 ( c ) ( 4 ) - - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635 ( c ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:16) / "Benzinga" (by Vandana Singh)
Why Is 2seventy bio Stock Trading Higher On Monday? - Legend Biotech ( NASDAQ:LEGN ) , Johnson & Johnson ( NYSE:JNJ ) , 2seventy bio ( NASDAQ:TSVT ) , Bristol-Myers Squibb ( NYSE:BMY )
Friday, the FDA's Oncologic Drugs Advisory Committee ( ODAC ) voted positively ( 8-3 ) favoring expanded use of Bristol Myers Squibb & Co BMY 2seventy bio Inc's TSVT Abecma ( idecabtagene vicleucel ) .
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:31) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers' ( BMY ) Abecma Gets ODAC Votes for Label Expansion
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
In Article Trend: Somewhat-Bullish
March 18, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Billionaire Bill Gates Has 35% of His Portfolio Invested in These 2 Artificial Intelligence ( AI ) Stocks: Are They No-Brainer Buys?
AI is a key growth driver for both of these stocks owned by the Gates Foundation Trust.
In Article Trend: Somewhat-Bullish
March 15, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Stock Moves -0.29%: What You Should Know
Bristol Myers Squibb (BMY) closed the most recent trading day at $52.34, moving -0.29% from the previous trading session.
In Article Trend: Somewhat-Bullish
March 15, 2024 (17:05) / "Benzinga" (by Vandana Singh)
Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy - Bristol-Myers Squibb ( NYSE:BMY )
The FDA granted accelerated approval on Thursday to Bristol Myers Squibb Co.'s BMY of Breyanzi ( lisocabtagene maraleucel, liso-cel ) , a CD19-directed chimeric antigen receptor ( CAR ) T cell therapy, for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
In Article Trend: Somewhat-Bullish
March 15, 2024 (16:12) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY - Bristol-Myers Squibb ( NYSE:BMY )
NEW YORK, March 15, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ( "Bristol Myers" or the "Company" ) BMY. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 15, 2024 (15:29) / "Benzinga" (by Vandana Singh)
What's Going On With Cancer Focused-Geron Stock On Friday? - Geron ( NASDAQ:GERN )
Friday, Geron Corporation's GERN shares are trading lower with a high session volume of 5.82 million compared to the average 100-day volume of 8.8 million, as per data from Benzinga Pro. Thursday, the FDA's Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of ...
In Article Trend: Neutral
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:14) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets FDA Nod for Breyanzi's Label Expansion
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In Article Trend: Neutral
March 14, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.49, signifying a -0.3% move from its prior day's close.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb Company ( BMY ) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
March 14, 2024 (12:28) / "Zacks Commentary" (by Zacks Equity Research)
UnitedHealth's ( UNH ) Payment System Disrupted by Cyberattack
A cyberattack on UnitedHealth's (UNH) payment management subsidiary, Change Healthcare, last month continues to impact healthcare services, especially cancer treatments, as payment processing remains disrupted.
In Article Trend: Neutral
March 14, 2024 (11:30) / "GlobeNewswire" (by Century Therapeutics)
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued ...
In Article Trend: Neutral
March 14, 2024 (11:30) / "GlobeNewswire" (by Purple Biotech Ltd.)
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated ...
In Article Trend: Neutral
March 13, 2024 (17:43) / "Benzinga" (by Vandana Singh)
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers - Johnson & Johnson ( NYSE:JNJ ) , Bristol-Myers Squibb ( NYSE:BMY )
On Friday, 15 March, the FDA's Oncologic Drugs Advisory Committee will meet to discuss Johnson & Johnson JNJ / Legend Biotech Corporation's LEGN supplemental biologics license application for Carvykti ( ciltacabtagene autoleucel ) for relapsed or refractory multiple myeloma, who have received at ...
In Article Trend: Neutral
March 12, 2024 (16:15) / "Benzinga" (by Benzinga Insights)
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity - Bristol-Myers Squibb ( NYSE:BMY )
Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 8 unusual trades. Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies.
In Article Trend: Neutral
March 12, 2024 (12:00) / "GlobeNewswire" (by Ikena Oncology)
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (20:10) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of ...
In Article Trend: Neutral
March 11, 2024 (20:10) / "Benzinga" (by Globe Newswire)
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CytomX Therapeutics ( NASDAQ:CTMX )
- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 ( EpCAM ADC ) Phase 1 clinical study initiation in solid tumors, including colorectal cancer ( CRC ) anticipated in the 1st half of 2024 -
In Article Trend: Neutral
March 11, 2024 (17:46) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb - Bristol-Myers Squibb ( NYSE:BMY )
Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with ...
In Article Trend: Neutral
March 11, 2024 (17:12) / "Investors Business Daily" (by Investor's Business Daily)
The $1 Billion Opportunity Driving This IBD Stock Of The Day Higher
Neurocrine Stock: The $1 Billion Opportunity Driving Shares Higher Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 9, 2024 (17:44) / "Forbes" (by Joshua Cohen)
Legal Challenges To IRA Drug Price Negotiations Face Skeptical Judges
A district court judge in New Jersey heard oral arguments this week with respect to claims brought forth by four pharmaceutical companies that the Inflation Reduction Act's drug price negotiation provision violates certain constitutional rights.
In Article Trend: Neutral
March 8, 2024 (20:02) / "PR Newswire" (by U.S. Food and Drug Administration)
FDA Roundup: March 8, 2024
SILVER SPRING, Md., March 8, 2024 /PRNewswire/ -- Today, the U.S.
In Article Trend: Bullish
March 7, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 7, 2024 (21:07) / "PR Newswire" (by Inc.)
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initiated clinical trial of Phase 1 P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T program
In Article Trend: Somewhat-Bullish
March 7, 2024 (19:52) / "Benzinga" (by Vandana Singh)
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - Arcellx ( NASDAQ:ACLX )
Morgan Stanley initiates Arcellx Inc ACLX, noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner. ddBCMA ( aka anito-cel ) is Arcellx's lead asset, incorporating its patent-protected D-domain as the extracellular binding domain.
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:31) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Down 6.5% Since Last Earnings Report: Can It Rebound?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 7, 2024 (12:59) / "Zacks Commentary" (by Zacks Equity Research)
Gilead ( GILD ) & MRK's HIV Oral Combo Shows Efficacy in Phase II
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
In Article Trend: Neutral
March 7, 2024 (06:15) / "Barrons" (by Josh Nathan-Kazis)
Biden Will Tout Lower Drug Prices in State of the Union. Big Pharma Might Be Losing the Fight.
Big Pharma Is Running Out of Time to Block Medicare Drug Price Negotiations ...
In Article Trend: Neutral
March 7, 2024 (06:00) / "GlobeNewswire" (by Ultimovacs ASA)
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
Oslo, March 7 2024: Ultimovacs ASA ( "Ultimovacs" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced topline results from the Phase II clinical trial, INITIUM ( NCT04382664 ) , evaluating the company's therapeutic cancer vaccine ...
In Article Trend: Neutral
March 6, 2024 (12:01) / "Benzinga" (by Globe Newswire)
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc.
In Article Trend: Neutral
March 6, 2024 (12:01) / "GlobeNewswire" (by iTeos Therapeutics Inc.)
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the ...
In Article Trend: Neutral
March 6, 2024 (11:59) / "Zacks Commentary" (by Zacks Equity Research)
3 DWS Mutual Funds to Buy for Alluring Returns
Invest in DWS mutual funds such as DCUSX, DESUX and KTCAX to build a diversified investment portfolio.
In Article Trend: Somewhat-Bullish
March 5, 2024 (21:45) / "Benzinga" (by Natan Ponieman)
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic - AstraZeneca ( NASDAQ:AZN ) , Bristol-Myers Squibb ( NYSE:BMY )
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenomics, access to healthcare and the U.S.' role in the world.
In Article Trend: Neutral
March 5, 2024 (17:58) / "Zacks Commentary" (by Zacks Equity Research)
Bayer ( BAYRY ) Acquires BridgeBio's Cardiovascular Drug
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
In Article Trend: Neutral
March 5, 2024 (12:55) / "GlobeNewswire" (by Purple Biotech Ltd.)
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
REHOVOT, Israel, March 05, 2024 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( "Purple Biotech" or "the Company" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug ...
In Article Trend: Neutral
March 5, 2024 (12:00) / "Canada Newswire" (by Inc.)
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial ... Canada ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (17:32) / "Benzinga" (by Benzinga Insights)
Bristol-Myers Squibb's Options Frenzy: What You Need to Know - Bristol-Myers Squibb ( NYSE:BMY )
Whales with a lot of money to spend have taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 75% of the investors opened trades with ...
In Article Trend: Neutral
March 4, 2024 (13:11) / "GlobeNewswire" (by Inc.)
Molecular Templates, Inc. Provides Interim Update
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer. Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer.
In Article Trend: Neutral
March 4, 2024 (13:00) / "Canada Newswire" (by Find Therapeutics Inc.)
Find Therapeutics Announces Appointment of Dr. Anthony Johnson to its Board of Directors
MONTREAL, March 4, 2024 /CNW/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced that Anthony Johnson, MBBS, MD has been appointed to the Company's Board of Directors effective March 4, 2024.
In Article Trend: Somewhat-Bullish
March 4, 2024 (12:30) / "GlobeNewswire" (by Inc.)
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (12:00) / "GlobeNewswire" (by Inc.)
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
SAN DIEGO, March 04, 2024 ( GLOBE NEWSWIRE ) -- Skye Bioscience, Inc. ( OTCQB: SKYE ) ( "Skye" or the "Company" ) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, ...
In Article Trend: Neutral
March 2, 2024 (17:41) / "GlobeNewswire" (by Ultimovacs ASA)
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
NON-REGULATORY PRESS RELEASE ...
In Article Trend: Neutral
March 1, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb ( BMY ) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $50.89, indicating a +0.28% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:58) / "CNN" (by Tami Luhby)
Judge upholds Medicare drug price negotiation program | Politics
Judge upholds Medicare drug price negotiation program, but more lawsuits are being considered in other courts ...
In Article Trend: Neutral
March 1, 2024 (19:02) / "CNBC" (by Annika Kim Constantino)
Judge rejects AstraZeneca's challenge to Medicare drug price negotiations
U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.
In Article Trend: Neutral
March 1, 2024 (12:00) / "Forbes" (by Marc Cooper)
Council Post: M&A Designed For A Low-Growth World
M&A Designed For A Low-Growth World Forbes ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (07:23) / "Stocknews.com" (by ABMN Staff)
Bristol-Myers Squibb ( NYSE:BMY ) Upgraded to Strong-Buy at StockNews.com
Bristol-Myers Squibb ( NYSE:BMY ) Upgraded to Strong-Buy at ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (07:22) / "Stocknews.com" (by Defense World Staff)
Bristol-Myers Squibb ( NYSE:BMY ) Upgraded to Strong-Buy at StockNews.com
Bristol-Myers Squibb ( NYSE:BMY - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report released on Friday. Other research analysts also recently issued reports about the stock.
In Article Trend: Somewhat-Bullish
February 29, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers Squibb Company ( BMY ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
February 29, 2024 (13:48) / "Benzinga" (by Meg Flippin)
Here's How Coeptis Therapeutics Is Innovating Cell Therapy Approaches - Actinium Pharma ( AMEX:ATNM ) , Bristol-Myers Squibb ( NYSE:BMY )
Acute myeloid leukemia ( AML ) is one of the most common types of leukemia in adults - with 20,800 new cases expected in the U.S. alone in 2024 - yet the treatments available today are insufficient. At the five-year mark, the survival rate for AML hovers around 28%.
In Article Trend: Neutral
February 28, 2024 (15:46) / "Benzinga" (by Vandana Singh)
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss - Eli Lilly and Co ( NYSE:LLY ) , Bristol-Myers Squibb ( NYSE:BMY )
Eli Lilly And Co's LLY CEO, David Ricks, shared the pharmaceutical giant's plans to introduce its obesity drug, tirzepatide, in India as early as next year. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss in the United States, holds promise for the Indian market.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website